LabCorp Receives 2017 Partnership Award from Be The Match®
November 13 2017 - 8:30AM
Business Wire
Award Recognizes 25 Years of Innovation and
Support to Help Cure Blood Cancers
LabCorp, (NYSE: LH), a leading global life sciences company that
is deeply integrated in guiding patient care, proudly announces
that it received the 2017 Partnership Award from Be The Match®
on November 11 at the nonprofit’s 30th Annual Council Meeting
in Minneapolis. LabCorp is a leader in providing specialized
laboratory testing necessary for tissue donation and for
twenty-five years has worked closely with Be the Match to
provide testing services to support bone marrow donations,
introducing many innovations to improve donor testing. The
prestigious award recognizes the long and successful partnership
between Be the Match and LabCorp to improve outcomes for patients
with blood cancers.
This press release features multimedia. View
the full release here:
http://www.businesswire.com/news/home/20171113005674/en/
Be The Match, operated by the National Marrow Donor Program®
(NMDP), is the world’s leading nonprofit organization focused on
saving lives through marrow and cord blood transplantation, which
can be a cure for someone with life-threatening blood cancers like
leukemia or lymphoma. The nonprofit organization also runs the Be
The Match Registry®, the world’s largest registry of potential bone
marrow donors and donated cord blood units. Since 1987, Be The
Match has made more than 80,000 transplants possible.
“LabCorp has been an exemplary partner from the very beginning
of our relationship,” said Jeffrey Chell, M.D., chief executive
officer emeritus of Be The Match. C. Randal Mills, Ph.D., chief
executive officer of Be The Match, added, “Countless lives have
been touched through LabCorp’s work to continually improve the
testing process and support greater awareness of the need for
donors. Be The Match appreciates LabCorp and its dedicated team,
and we look forward to working together in the future.”
LabCorp and Be The Match have worked closely together to improve
the quality, efficiency and convenience of donor match testing,
which assesses the patient’s and donor’s human leukocyte antigen
(HLA, or tissue type) to identify tissue donations most likely to
be accepted by the patient, helping to improve treatment success.
During their collaboration, LabCorp has continually enhanced the
quality and convenience of HLA testing, including the introduction
of DNA-based molecular HLA testing and buccal swab specimen
collection in place of traditional venous blood collection. Be The
Match worked with LabCorp on a pilot program to evaluate the new
collection method, and it now uses buccal swabs for all of its
donor collections, making it easier for potential donors to be
added to the Be The Match Registry. Throughout their partnership,
LabCorp’s nationwide network of collection sites and standardized
testing have provided Be The Match with a single lab to support the
full range of testing needs for donors and patients.
Their joint efforts have also helped to expand the donor
database by publicizing the need for more potential donors to be
tested, with LabCorp hosting donor drives for its employees and
welcoming Be The Match recipients to tell their stories at LabCorp
events. LabCorp has also sponsored many fundraising drives to
support the donor registry program. By working closely together for
more than a quarter century, LabCorp and Be The Match have helped
to make better matches and expand the donor database, improving
outcomes for more patients.
“LabCorp is honored to receive this award from our great friends
at Be The Match,” said Jon Meltzer, Ph.D., LabCorp senior vice
president for esoteric and specialty testing, who accepted the 2017
Partnership Award on behalf of LabCorp. “Our mission is to improve
health and improve lives, and Be The Match is a perfect example of
what that means, as their work has profoundly affected thousands of
lives. We are proud to work with them to help make that success
possible.”
About LabCorp
LabCorp (NYSE: LH), an S&P 500 company, is a leading global
life sciences company that is deeply integrated in guiding patient
care, providing comprehensive clinical laboratory and end-to-end
drug development services. With a mission to improve health and
improve lives, LabCorp delivers world-class diagnostic solutions,
brings innovative medicines to patients faster and uses technology
to improve the delivery of care. LabCorp reported net revenues of
nearly $9.5 billion for 2016. To learn more about LabCorp, visit
www.labcorp.com, and to learn more about Covance Drug Development,
visit www.covance.com.
Forward-Looking Statements
This press release contains forward-looking statements including
with respect to estimated 2017 guidance and the impact of various
factors on operating and financial results. Each of the
forward-looking statements is subject to change based on various
important factors, including without limitation, competitive
actions in the marketplace, and adverse actions of governmental and
other third-party payers. Actual results could differ materially
from those suggested by these forward-looking statements. The
Company has no obligation to provide any updates to these
forward-looking statements even if its expectations change. Further
information on potential factors that could affect operating and
financial results is included in the Company’s Form 10-K for the
year ended December 31, 2016, and subsequent Forms 10-Q, including
in each case under the heading risk factors, and in the Company’s
other filings with the SEC. The information in this press release
should be read in conjunction with a review of the Company’s
filings with the SEC including the information in the Company’s
Form 10-K for the year ended December 31, 2016, and subsequent
Forms 10-Q, under the heading MANAGEMENT’S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
About Be The Match
For people with life-threatening blood cancers—like leukemia and
lymphoma—or other diseases, a cure exists. Be The Match connects
patients with their donor match for a life-saving marrow or
umbilical cord blood transplant. People can contribute to the cure
as a member of the Be The Match Registry, financial contributor or
volunteer. Be The Match provides patients and their families
one-on-one support, education, and guidance before, during and
after transplant.
Be The Match is operated by the National Marrow Donor Program®
(NMDP), a nonprofit organization that matches patients with donors,
educates health care professionals and conducts research so more
lives can be saved. To learn more about the cure, visit
BeTheMatch.org or call 1 (800) MARROW-2.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171113005674/en/
LabCorpMedia Relations:Donald Von Hagen,
336-436-8263orInvestor Contact:Scott Frommer,
336-436-5076
Labcorp (NYSE:LH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Labcorp (NYSE:LH)
Historical Stock Chart
From Sep 2023 to Sep 2024